Retatrutide

Also known as: LY3437943, triple incretin agonist

Evidence Tier Cmed-high riskadvancedinvestigational

Investigational triple-agonist obesity drug candidate with early human weight-loss data but no approval.

FDA Safety Flag

The FDA has identified this substance as one that may present significant safety risks when used in compounding, including concerns about immunogenicity, impurity characterization, and/or insufficient safety information.

Overview

Retatrutide is an investigational multi-agonist metabolic peptide studied for obesity and metabolic disease. Early trial readouts suggest very large weight-loss potential, but published human evidence is still limited compared with approved incretin drugs. It is not approved, and FDA has taken a hard line against compounding unapproved agents in this class.

Research Details

Mechanism of Action

Multi-receptor incretin agonism intended to amplify appetite suppression, insulin signaling, and energy-balance effects beyond GLP-1 alone.

Study Dose Range

Early human studies use multi-mg weekly subcutaneous dosing; no approved regimen exists.

Administration Routes

subcutaneous

Onset / Timeline

Expected to follow other incretin agents, with early appetite effects and larger changes over months.

Expected Effects

Preliminary human data suggest strong body-weight reduction and metabolic benefit, but the evidence base remains early-stage.

Adverse Effects

Likely significant GI intolerance profile with limited long-term safety clarity. Broader risk remains uncertain due to limited human exposure.

Contraindications

Experimental compound; avoid outside regulated research or clinician-supervised contexts.

Interaction Notes

Assume class-like overlap with GLP-1 and GIP therapies; avoid layering with other incretin agents.

Related Goals

Fat Loss & Metabolism

Known Interactions

contraindicated with Semaglutide

Approved GLP-1 therapy should not be layered with an investigational multi-incretin agent.

contraindicated with Tirzepatide

Two high-potency incretin agonists compound GI and glucose-management risk.

contraindicated with Liraglutide

Do not layer a daily GLP-1 agonist with an investigational triple-agonist compound.

Available From

Amino Club

consumer RUO · COA: product page COA viewer

GLP-3 product page (variant-dependent) · variant-dependent on product page

Consumer RUO; review product details carefully

Amino Club currently appears to place retatrutide under a GLP-3 product page, so that naming mismatch should be noticed before purchase.

USVisit Vendor

QC: third-party purity testing; product-level COA on page

Shipping: US/ROW (verify current policy) · affiliate: public program

Read this before you compare products

How to Compare Peptide Vendors

A practical vendor comparison guide that helps you look past branding and focus on the details that actually matter.

Read guide

Frequently Compared

CJC-1295

Long-acting GHRH analogue studied in human trials for sustained GH/IGF-1 elevation.

Tier B

Tesamorelin

FDA-approved GHRH analogue for HIV-associated lipodystrophy. Prescription only.

Tier A

Ipamorelin

Selective GHSR agonist profiled for more targeted GH release with less ACTH/cortisol spillover than earlier secretagogues.

Tier B-C

GHRP-2

GH secretagogue studied in human stimulation tests with documented endocrine spillover effects.

Tier B

Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.